Prestige Consumer Healthcare Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.prestigebrands.com

Earnings Score
Moat Score
Safety Score

Market Cap $4.19B
PE 20
Debt $1.06B
Cash $51.54M
EV $5.20B
FCF $254.64M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$205.95M
EBIT	$324.36M
ROE	12%
ROA	10%
FCF	$254.64M
Equity	$1.73B
Growth Stability	-48%
PE	20.33
PEG	5.81
PB	2.42
P/FCF	16.44
P/S	3.77
Price/Cash	0.01
Debt/Equity	0.61
Debt/FCF	4.16
Net Margins	19%
Gross Margins	55%
Op. Margins	29%
Earnings CAGR	4%
Sales Growth YoY	-1%
Sales Growth QoQ	6%
Sales CAGR	3%
FCF CAGR	5%
Equity CAGR	11%
Earnings Stability	0.09
Earnings Growth YoY	2%
Earnings Growth QoQ	11%

Earnings CAGR 5Y	4%
Sales CAGR 5Y	5%
FCF CAGR 5Y	3%
Equity CAGR 5Y	8%
Earnings CAGR 3Y	2%
Sales CAGR 3Y	2%
FCF CAGR 3Y	0%
Equity CAGR 3Y	3%
Market Cap	$4.19B
Revenue	$1.11B
Assets	$3.32B
Total Debt	$1.06B
Cash	$51.54M
Shares Outstanding	49.65M
EV	5.2B
Earnings Score	7%
Moat Score	92%
Safety Score	57%
Final Score	52%
Working Capital	273.8M
Current Ratio	3.56
Gross Profit	$613.16M
Shares Growth 3y	-0%
Equity Growth QoQ	3%
Equity Growth YoY	13%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Prestige Consumer Healthcare is an American company that distributes branded over-the-counter healthcare and household cleaning products to mass merchandisers, drugstores, convenience stores, supermarkets, and e-commerce channels. The firm's major brands include BC/Goody's, Chloraseptic, Clear Eyes, Compound W, Debrox, Dramamine, Fess, Fleet, Gaviscon, Hydralyte, Monistat, Nix, and Summer's Eve. The company's portfolio includes branded products in women's health, gastrointestinal, analgesics, eye and ear care, dermatological products, oral care, skincare, sleep aids, and cough and cold. Its segments include North American OTC Healthcare and International OTC Healthcare.

SEC Filings

Direct access to Prestige Consumer Healthcare Inc. (PBH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does Prestige Consumer Healthcare Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Prestige Consumer Healthcare Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%

Stability 9%

loading chart...

Prestige Consumer Healthcare Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Prestige Consumer Healthcare Inc..

Years

Calculation mode

= $3.6B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$255M	$268M	$282M	$296M	$311M	$328M	$344M	$362M	$381M	$401M	$421M	$4.2B
DCF		$243M	$233M	$222M	$213M	$203M	$194M	$186M	$178M	$170M	$162M	$1.6B
Value	$3.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	11%	12%	8%	33%	-4%	15%	17%	19%	-7%	19%	19%
ROA	-	9%	5%	6%	2%	8%	9%	9%	-1%	10%	10%
ROE	-	13%	8%	29%	-3%	12%	12%	13%	-6%	13%	12%

Good Net Margins (18.78%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	9.68	15.35	10.19	10.14	8.61	7.01	5.97	6.13	4.74	4.16
Debt over Equity	2.54	2.22	2.7	1.71	1.65	1.49	1.1	0.95	0.94	0.69	0.61
Growth Stability	-	-	-	100%	-21%	100%	100%	100%	-48%	100%	-48%

Bad Debt/FCF ratio (4.16)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.61)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-48%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	13%	9%	18%	-6%	-1%	-2%	15%	4%	-0%	5%
Earnings YoY growth	-	28%	-31%	389%	-111%	-497%	16%	25%	-140%	-354%	4%
Equity YoY growth	-	19%	11%	43%	-7%	7%	16%	16%	-8%	14%	8%
FCF YoY growth	-	14%	-15%	36%	-10%	13%	5%	17%	-11%	8%	3%